Literature DB >> 1759840

Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine blastomycosis.

K V Clemons1, D A Stevens.   

Abstract

Amphotericin B as a lipid complex and as a deoxycholate suspension (Fungizone) was tested against murine blastomycosis. All doses of each form prolonged survival (P less than 0.05 to 0.001). Fungizone was more effective than lipid complex at doses of 0.8 mg/kg of body weight. However, lipid complex at 12.8 mg/kg was not toxic and superior in efficacy (P less than 0.001) to 2.0 mg of Fungizone per kg (a toxic dose), and it cleared all animals of infection. Lipid complex is an effective therapy for murine blastomycosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1759840      PMCID: PMC245343          DOI: 10.1128/AAC.35.10.2144

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Treatment of systemic fungal infections with liposomal amphotericin B.

Authors:  G Lopez-Berestein; G P Bodey; V Fainstein; M Keating; L S Frankel; B Zeluff; L Gentry; K Mehta
Journal:  Arch Intern Med       Date:  1989-11

2.  Liposomes as carriers of antifungal drugs.

Authors:  G Lopez-Berestein
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

3.  Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in mice.

Authors:  C Tremblay; M Barza; C Fiore; F Szoka
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

4.  Treatment of invasive Aspergillus sinusitis with liposomal-amphotericin B.

Authors:  R S Weber; G Lopez-Berestein
Journal:  Laryngoscope       Date:  1987-08       Impact factor: 3.325

5.  Activity of ICI 195,739, a new oral triazole, compared with that of ketoconazole in the therapy of experimental murine blastomycosis.

Authors:  R M Tucker; L H Hanson; E Brummer; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

6.  Mouse model of pulmonary blastomycosis: utility, simplicity, and quantitative parameters.

Authors:  R P Harvey; E S Schmid; C C Carrington; D A Stevens
Journal:  Am Rev Respir Dis       Date:  1978-04

7.  Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes.

Authors:  T F Patterson; P Miniter; J Dijkstra; F C Szoka; J L Ryan; V T Andriole
Journal:  J Infect Dis       Date:  1989-04       Impact factor: 5.226

8.  Treatment of mycoses with itraconazole.

Authors:  R M Tucker; P L Williams; E G Arathoon; D A Stevens
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

9.  Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B.

Authors:  F C Szoka; D Milholland; M Barza
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

10.  Hepatosplenic fungal infection: CT and pathologic evaluation after treatment with liposomal amphotericin B.

Authors:  A Shirkhoda; G Lopez-Berestein; J M Holbert; M A Luna
Journal:  Radiology       Date:  1986-05       Impact factor: 11.105

View more
  12 in total

1.  Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.

Authors:  Jon A Olson; Jill P Adler-Moore; Julie Schwartz; Gerard M Jensen; Richard T Proffitt
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 2.  Murine models of blastomycosis, coccidioidomycosis, and histoplasmosis.

Authors:  K N Sorensen; K V Clemons; D A Stevens
Journal:  Mycopathologia       Date:  1999       Impact factor: 2.574

3.  Comparison of fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis.

Authors:  K V Clemons; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

4.  In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important?

Authors:  C E Swenson; W R Perkins; P Roberts; I Ahmad; R Stevens; D A Stevens; A S Janoff
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

5.  Efficacy of nikkomycin Z against experimental pulmonary blastomycosis.

Authors:  K V Clemons; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

6.  Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats.

Authors:  R Bhamra; A Sa'ad; L E Bolcsak; A S Janoff; C E Swenson
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 7.  Carrier effects on biological activity of amphotericin B.

Authors:  J Brajtburg; J Bolard
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

Review 8.  Clinical and laboratory update on blastomycosis.

Authors:  Michael Saccente; Gail L Woods
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

Review 9.  Diversity of lipid-based polyene formulations and their behavior in biological systems.

Authors:  K M Wasan; G Lopez-Berestein
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

10.  Comparative neurotoxicities of amphotericin B and its mono-methyl ester derivative in rats.

Authors:  K R Reuhl; M Vapiwala; M T Ryzlak; C P Schaffner
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.